Predicting neoadjuvant chemotherapy treatment response in hormone- receptor-positive/HER2-negative breast cancer - results from the Swedish SCAN-B population-based cohort.

ABSTRACT:

Background and purpose

Hormone-receptor-positive/HER2-negative (HR+/HER2-) early-stage breast cancers (EBCs) display heterogenous responses to neoadjuvant chemotherapy (NACT) warranting biomarkers to tailor optimal treatment for individual patients.

Patients/material and methods

Women with HR+/HER2- EBC (N = 178) included in the Swedish Sweden Cancerome Analysis Network-Breast (SCAN-B) population-based cohort (2010-2019) treated with NACT were included. We analyzed rates of pathologic complete response (pCR), objective response (OR), breast conserving surgery (BCS), and recurrence-free interval (RFI) in subgroups defined by baseline clinicopathological and molecular characteristics.

Results

The pCR rate was low (6%); nonetheless, after a median follow-up of 5.41 years

SUBMITTER: Loman N 

PROVIDER: S-EPMC12645220 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature